233 results on '"del Papa, Nicoletta"'
Search Results
2. Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?
3. Dysregulation of circulating collagen turnover markers in very early systemic sclerosis
4. Response to antifibrotic therapy and decrease of circulating BAG3 protein levels in systemic sclerosis patients with reduced forced vital capacity
5. Does the impact of COVID-19 on patients with systemic sclerosis change over time?
6. Herpes zoster in lupus nephritis: experience on 292 patients followed up for 15 years
7. Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients
8. Does the impact of COVID‐19 on patients with systemic sclerosis change over time?
9. High NEMO score values in nailfold videocapillaroscopy are associated with the subsequent development of ischaemic digital ulcers in patients with systemic sclerosis
10. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study
11. NEMO score in nailfold videocapillaroscopy is a good tool to assess both steady state levels and overtime changes of disease activity in patients with systemic sclerosis: a comparison with the proposed composite indices for this disease status entity
12. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
13. Profibrotic Effects of Endothelin-1 on Fibroblasts Are Mediated by Aldosterone In Vitro: Relevance to the Pathogenesis and Therapy of Systemic Sclerosis and Pulmonary Arterial Hypertension
14. Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches
15. Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study
16. A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies
17. Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey
18. Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT
19. Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: Checklists for Clinical Practice
20. Is adipose-tissue (or its fraction) grafting really effective in the treatment of scleroderma hand?
21. Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren’s Syndrome
22. Management of Sjögren's Syndrome: Present Issues and Future Perspectives
23. Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases : Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT
24. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19 : EBMT guidelines and recommendations
25. Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: Checklists for Clinical Practice
26. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: The UPSIDE study protocol
27. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study
28. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
29. The Role of Interferons in the Pathogenesis of Sjögren’s Syndrome and Future Therapeutic Perspectives
30. Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19 infection
31. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases : updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
32. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient)
33. The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak
34. Nailfold Videocapillaroscopy Is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients
35. Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis
36. Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?
37. Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis
38. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
39. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
40. Sjögrenʼs syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögrenʼs syndrome, derived from an analysis of a cohort of Italian patients
41. Bone Marrow Endothelial Progenitors are Defective in Systemic Sclerosis
42. Precocious Intima-Media Thickening in Patients With Primary Sjögrenʼs Syndrome
43. Increased levels of circulating endothelial cells in chronic periaortitis as a marker of active disease
44. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
45. Circulating Endothelial Cells as a Marker of Ongoing Vascular Disease in Systemic Sclerosis
46. Autoantibodies to Fibroblasts Induce a Proadhesive and Proinflammatory Fibroblast Phenotype in Patients With Systemic Sclerosis
47. Iloprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al
48. Gene Expression Profiles in Primary Sjögren's Syndrome With and Without Systemic Manifestations
49. Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1
50. Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.